Latham & Watkins advised CHEPLAPHARM on the offering. CHEPLAPHARM Arzneimittel GmbH announced the issuance of €750 million aggregate principal amount of New York law 144A/Reg S senior...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised CHEPLAPHARM on the deal and on the bridge loan. CHEPLAPHARM Arzneimittel GmbH announced the acquisition of the worldwide commercial rights (excluding South Korea)...
You must be a Standard 1 Year member to access this content.
Latham & Watkins has advised CHEPLAPHARM AG on the deal. CHEPLAPHARM AG (CHEPLAPHARM), a leading international platform for well-established branded medicines, announced its agreement for a...
You must be a Standard 1 Year member to access this content.
Freshfields Bruckhaus Deringer advised Cheplapharm Arzneimittel GmbH on the deal, Cheplapharm Arzneimittel GmbH (‘Cheplapharm’) signed an agreement with Astellas Pharma Inc., a Japan based pharmaceutical company,...
You must be a Standard 1 Year member to access this content.
